Related Experiment Videos
Total pelvic exenteration. A 50-year experience at the Ellis Fischel Cancer Center
M J Lopez1, S B Standiford, J L Skibba
1Department of Surgery, St Elizabeth's Medical Center of Boston, Tufts University School of Medicine, Mass.
Archives of Surgery (Chicago, Ill. : 1960)
|April 1, 1994
Summary
Total pelvic exenteration for advanced pelvic cancer shows declining operative mortality and morbidity over 50 years. This surgical approach remains crucial for treating complex pelvic malignancies, with a 42% 5-year survival rate.
Area of Science:
- Oncology
- Surgical Oncology
- Pelvic Cancer Treatment
Background:
- Advanced pelvic cancer presents significant treatment challenges.
- Total pelvic exenteration is a radical surgical option for these cases.
- Long-term outcomes require continuous evaluation.
Purpose of the Study:
- To evaluate a 50-year experience with total pelvic exenteration.
- To analyze trends in outcomes for advanced pelvic cancer treatment.
- To assess the role of exenteration in oncological management.
Main Methods:
- Retrospective analysis of 232 patients undergoing total pelvic exenteration.
- Data collected from a specialized cancer hospital.
- Comprehensive follow-up ensuring complete data integrity.
Main Results:
- Overall 5-year survival rate was 42%.
- Morbidity rate was 45%, with operative mortality at 14%.
- Operative mortality decreased significantly in later decades.
Conclusions:
- Total pelvic exenteration outcomes have improved over 50 years.
- Improved patient selection and perioperative care reduced mortality and morbidity.
- Exenteration remains a vital treatment for advanced pelvic cancers.